How have RSPID shares performed in 2024?

RespireRx Pharmaceuticals' stock was trading at $0.0009 at the beginning of 2024. Since then, RSPID stock has decreased by 5.6% and is now trading at $0.0009. View the best growth stocks for 2024 here .

How do I buy shares of RespireRx Pharmaceuticals?

Shares of RSPID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:RSPID

RespireRx Pharmaceuticals (RSPID) Stock Price, News & Analysis

→ The Gold Grab of the Century (From Colonial Metals) (Ad)

Free RSPID Stock Alerts

$0.0009

0.00 (0.00%)

(As of 04/26/2024 ET)

Compare

Today's Range: $0.0009
▼
$0.0009
50-Day Range: N/A
52-Week Range: $0.01
▼
$1.50

Volume: 3.73 million shs
Average Volume: 928,930 shs
Market Capitalization: $61,430.35

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart

Get RespireRx Pharmaceuticals alerts:

Ad Colonial Metals

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

About RespireRx Pharmaceuticals

RespireRx Pharmaceuticals Inc. engages in the discovery and development of pharmaceuticals for the treatment of respiratory disorders. It has two drug platforms comprising ampakines, which are small molecule compounds to enhance the excitatory actions of the neurotransmitter glutamate at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor complex; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. The company's lead ampakine, CX1739, which is in Phase II clinical studies for drug-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven respiratory disorders, neurobehavioral disorders, spinal cord injury, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was founded in 1987 and is headquartered in Glen Rock, New Jersey.

RSPID Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RSPID Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive RSPID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RespireRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:RSPID
CUSIP: N/A
CIK: N/A
Web: www.respirerx.com
Phone: 201 444 4947
Fax: N/A
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 72,271,000
Free Float: N/A
Market Cap: $61,430.35
Optionable: Not Optionable
Beta: 0.15

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Arnold S. Lippa (Age 74)
Exec. Chairman & Chief Scientific Officer
Comp: $339.6k
Dr. Jeff Eliot Margolis (Age 65)
Sr. VP, CFO, Treasurer, Sec. & Director
Comp: $321.6k
Mr. Richard D. Purcell (Age 60)
Sr. VP of R&D
Comp: $199.86k
Mr. Timothy L. Jones (Age 48)
Pres, CEO & Director
Mr. David Dickason (Age 58)
Sr. VP of Pre-Clinical Product Devel.
Mr. Marc M. Radin
Controller
Dr. Arvid Carlsson (Age 98)
Consultant

Key Competitors

View All Competitors

RSPID Stock Analysis - Frequently Asked Questions

How have RSPID shares performed in 2024?: RespireRx Pharmaceuticals' stock was trading at $0.0009 at the beginning of 2024. Since then, RSPID stock has decreased by 5.6% and is now trading at $0.0009.
View the best growth stocks for 2024 here.
How do I buy shares of RespireRx Pharmaceuticals?: Shares of RSPID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:RSPID) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial